Veterinary Analgesics and Anti-Inflammatory Market Size, Share & Trends Analysis Report By Drug Class (Non-Steroidal Anti-Inflammatory Drugs, Opioids & Partial Agonists, Local Anaesthetics/Nerve Blocks, Others), By Route of Administration (Oral Solids, Oral Liquids, Injectable, Transdermal/Topical, Others), By Animal Class (Companion Animals, Equine, Production/Food Animals, Others), By Indication (Postoperative/Perioperative Pain Control, Others), By Distribution Channel (Veterinary Hospitals & Clinics, Online Pharmacies, Others), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Veterinary Analgesics and Anti-Inflammatory Market Size & Growth Analysis

The global veterinary analgesics and anti-inflammatory market size was valued at USD 2.76 billion in 2025 and is projected to grow from USD 2.95 billion in 2026 to USD 4.99 billion by 2034, registering a CAGR of 6.8% during the forecast period from 2026 to 2034. North America dominated the veterinary analgesics and anti-inflammatory market with a market share of 32.2% in 2025.

The veterinary analgesics and anti-inflammatory market encompasses NSAIDs, opioids/partial agonists, monoclonal antibodies, and adjunctive therapies used for acute surgical pain, chronic musculoskeletal pain, and inflammatory conditions across companion animals and livestock. Regulatory and welfare pressures, particularly in developed markets, increase routine pain management in production animals and companion care.

Drug Class Insights

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used analgesics in veterinary medicine. They are effective for post-surgical pain, arthritis, and inflammatory conditions in dogs, cats, horses, and farm animals. Their growth is supported by affordability, well-documented safety, and strong clinician familiarity. Many veterinary guidelines recommend NSAIDs as first-line therapy, making them routine in clinics and farms. Their broad approvals, ease of dosing, and low regulatory complexity compared to opioids ensure they remain the leading drug class.

Request Customizationto receive a tailored report.

Route of Administration Insights

Injectable formulations, especially long-acting depot injections, are growing rapidly because they provide reliable dosing and reduce the risk of owner error. In clinics, they are favored for surgeries and chronic conditions where monthly biologics require professional administration. For farm animals, long-acting injections reduce handling frequency, aligning with welfare-driven practices. As regulatory approvals expand for injectable biologics, veterinarians increasingly prefer them over oral options, despite higher cost, because they combine effectiveness, convenience, and compliance benefits for both owners and animals.

Animal Class Insights

Companion animals like dogs and cats account for most veterinary analgesic sales because owners are willing to spend more on their care compared to livestock. Ageing pet populations are increasing cases of osteoarthritis, a condition requiring ongoing pain management. Owners often view pets as family members, which boosts demand for advanced treatments such as monthly monoclonal antibodies or long-acting transdermal patches. Clinics adopt standard pain protocols and prefer clinic-administered therapies, ensuring consistent prescribing.

Indication Insights

Chronic musculoskeletal disorders, particularly osteoarthritis in ageing dogs and cats, represent the largest therapeutic need. Osteoarthritis requires lifelong treatment and regular veterinary monitoring, creating steady demand for analgesics. Historically, NSAIDs dominated, but new biologics now offer monthly alternatives that generate higher revenue per patient. Veterinary guidelines increasingly recommend early diagnosis and multimodal therapy, combining drugs with physiotherapy. This structured approach ensures chronic pain remains the most important driver of prescriptions and long-term market value.

Distribution Channel Insights

Veterinary hospitals and clinics are the main distribution points for analgesics. Many high-value therapies, such as biologics, controlled opioids, and depot injectables, require veterinary supervision. Clinics administer pain control during surgeries, provide monthly injections for osteoarthritis, and dispense products like Zorbium transdermal patches for cats. Clinics also benefit financially from recurring visits tied to pain management. Manufacturers support this channel by training veterinarians and offering clinic programs, ensuring that veterinary practices remain the central hub for analgesic distribution worldwide.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America’s market dominance is driven by high pet ownership numbers, strong per-household veterinary spending, and a dense clinical and specialty hospital network that adopts novel therapeutics rapidly. The AVMA (2024) reports nearly 90 million dogs and 74 million cats in the U.S., creating a vast customer base. Regulatory clarity from the FDA Center for Veterinary Medicine supports timely approvals but also enforces rigorous post-market monitoring. Clinics in the U.S. and Canada are early adopters of subscription models for monthly biologics and bundled rehabilitation services. Strong welfare standards and high household expenditure ensure North America remains the dominant market.

U.S. Market Trends

The U.S. is the largest market for veterinary analgesics, supported by high pet ownership and strong household spending on pet healthcare. According to the AVMA, there are about 89.7 million dogs and 73.8 million cats in the country, driving steady demand for chronic pain management (e.g., osteoarthritis) and peri-operative analgesia. Clinics adopt premium therapies such as biologics and long-acting injectables quickly, supported by a strong clinical infrastructure, supporting overall market growth in the U.S.

Canada Market Trends

Canada’s veterinary analgesics market is driven by rising pet ownership, higher household spending, and strong professional guidance from the Canadian Veterinary Medical Association (CVMA). Companion-animal demand is growing steadily, though adoption of high-cost biologics varies by region due to clinic access and owner affordability. Government emphasis on animal welfare and transparent pricing discussions is shaping future adoption. Flexible pricing strategies and clinic education programs are key tools for manufacturers to strengthen market penetration.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific - Fastest-growing region

The Asia Pacific region is the fastest-growing market, driven by rapid urbanization, rising pet ownership, and government initiatives in animal health. China and India have seen large increases in veterinary infrastructure, with expanding clinics and rising household spending on pets. In 2024, India’s Standard Veterinary Treatment Guidelines included welfare-linked pain management protocols, promoting adoption in livestock as well. While affordability challenges remain, especially in production animals, demand for cost-effective long-acting injectables is rising. Global companies are accelerating local product filings and partnerships in the Asia Pacific, recognizing its dual growth track of mass-market livestock demand and a rapidly expanding companion-animal premium segment.

China Market Growth Factors

China is one of the fastest-growing veterinary analgesics market, driven by rapid urbanization and rising disposable incomes. Younger pet owners are more willing to pay for advanced healthcare, fueling demand for osteoarthritis treatments and peri-operative analgesia. Government initiatives to modernize veterinary regulation and welfare standards support expansion in both companion and production animals. Multinationals are investing in local partnerships and registrations, while demand for long-acting injectables is increasing in farms to meet welfare and compliance needs.

Indian Market Trends

India’s veterinary analgesics market is shaped by its dual focus: a massive livestock population and growing companion-animal demand in cities. The Department of Animal Husbandry and Dairying (DAHD) published Standard Veterinary Treatment Guidelines in October 2024, which encourage formal pain management in farm animals. In urban centers, rising pet ownership and new private clinics are increasing demand for osteoarthritis and chronic-care therapies.

Competitive Landscape

The global market is highly fragmented, dominated by large animal-health companies alongside regional specialists. Large players in premium biologics, NSAIDs, and subscription models. Mid-sized firms emphasize niche formulations and fast regional launches. Distribution-focused players and online pharmacies increase access to NSAIDs and topicals. Education, clinic partnerships, and pharmacovigilance remain core strategies across the sector.

Zoetis - A Market Leader

Zoetis leads the veterinary analgesics market with a broad portfolio of biologics and NSAIDs. Its strategy centers on clinic-administered premium therapies and post-market safety monitoring. The company’s Librela® (bedinvetmab) is the first monoclonal antibody approved for canine osteoarthritis pain and has quickly become a flagship product.

Latest News:

• In February 2025, Zoetis announced a U.S. label update for Librela, reflecting safety data and strengthening clinician confidence.

List of Key and Emerging Players in Veterinary Analgesics and Anti-Inflammatory Market